Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for depressive and negative symptoms in schizophrenia
2019-004489-16Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of esketamine in schizophrenia, schizophreniform disorder and schizoaffective disorder (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Change in Scale for the Assessment of Negative Symptoms. Started Sep 2021; status: completed.
02
Drugs
esketamine
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorder
Beyond the preview
Go deeper on 2019-004489-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004489-16.